Sanofi has announced today that its Nasacort Allergy 24HR triamcinolone acetonide nasal spray for the treatment of nasal allergies will be available over-the-counter beginning in spring 2014 now that the FDA has approved it as an OTC product. Sanofi’s consumer healthcare division, Chattem, Inc. will market the product.
An FDA advisory committee recommended approval of over-the-counter Nasacort spray in July 2013, while patient advocacy group Allergy & Asthma Network Mothers of Asthmatics (AANMA) opposed approval.
Sanofi US President, North America Pharmaceuticals, Anne Whitaker commented, “We believe there is significant value in making certain types of medicines, like Nasacort, directly available to consumers. Allergy sufferers will benefit from having an additional treatment option and it’s a strong addition to our existing consumer health portfolio.”
Chattem CEO Zan Guerry said, “By adding Nasacort to Chattem’s growing consumer healthcare portfolio, we are expanding our successful OTC allergy offering that includes the Allegra family of products.”
Read the Sanofi press release.
